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Summary
Objective: Giant cell tumors (GCT) of bone are benign tumors with local aggressiveness that
most of the time occur around the metaphyseal area of long bones, often in contact with the
articular cartilage. Their treatment remains controversial because of their high recurrence
rate. The authors report a retrospective series of 30 cases treated using curettage followed
by cementation. They suggest demonstrating the mechanical and functional beneﬁt of this
technique, its beneﬁt controlling the risk of recurrence, and of osteoarthritis potential.
Material and Methods: Between 1992 and 2005, 30 patients with GCT were treated using curet-
tage and cementation. Twenty-six of these tumors were present around the knee: 14 at the
distal femur and 12 at the proximal tibia. Preoperative radiological evaluation with standard
X-rays showed that the tumor measured a mean 71× 45mm, for a mean volume of 78 cm3.
Seventy-three percent of these GCT were in direct contact with the articular cartilage and 40%
extended to the soft tissues as seen on the CAT scan and/or MRI. All patients were treated with
curettage and cementation, 16 additional internal ﬁxation procedures were performed. The
mean follow-up of this series was 6 years and 4months. All patients continue to be monitored,
with none lost to follow-up.
Results: In all our cases, nine recurrences (30%) were observed during the ﬁrst 2 years. Six
patients were treated with a new curettage and cementation procedure and three underwent
a total knee arthroplasty. None of these lesions had recurred at the last follow-up. The MSTS
score, reﬂecting the function of the operated limb was a mean 93.33% (28± 2/30). Standard
radiological assessment showed a thin scalable border on four patients and was normal for
the all-total arthroplasty cases. Two cases of minor osteoarthritis progression were noted (one
less than 50% and a simple densiﬁcation of subchondral bone), requiring no speciﬁc treatment.
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An even lower rate of recurrence may be obtained through development of additional adjuvant
treatments such as calcitonin and bisphosphonates.
Level of evidence: Level IV; Therapeutic study.
© 2009 Elsevier Masson SAS. All rights reserved.
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•Introduction
Giant cell tumors (GCT) of bone are benign tumors with
local aggressiveness that most frequently occur around
the metaphyseal area of long bones, with frequent inva-
sion of subchondral bone, often in contact with joint
cartilage. These are relatively frequent tumors, account-
ing for 4—5% of bone tumors and 21% of benign tumors
of the bone according to Babinet [1] and Campanacci
et al. [2]. Joint extension is exceptional. Treatment of
the periarticular tumors remains controversial because of
the high recurrence rate. Resection treats the tumor and
prevents the risk of recurrence at the cost of a less desir-
able functional result. Simple tumor curettage makes joint
preservation possible, with a better functional result, but
the recurrence rate is higher: approximately 30—50% in
the series reported by Babinet [1], Campanacci et al.
[2], and Sung et al. [3]. This is why various adjuvant
measures have been taken: intraoperative use of phenol
[1], cryotherapy by Malawer et al. [4] and Marcove et
al. [5], combined with cementation with acrylic cement
[1].
According to Turcotte et al. [6], the curettage and
cementation technique with acrylic cement has the advan-
tages of preservation of dynamic stability, thus allowing
rapid loading, early detection of recurrence with radio-
logical observation of lysis at the cement—bone interface,
as well as the toxic properties of the methylmethacry-
late monomer and the necrotic effect of the heat
given off during polymerization on the tumor cells. It
can also be used at the onset of pathological frac-
ture. Nevertheless, the contact of the cement with
cartilage can damage the cartilage, possibly generat-
ing osteoarthrosis, which has been studied by Vult Von
Steyern et al. [7]. Thus, the problem of recurrence is
raised.
We have studied the results of this method on the
recurrence rate and the iatrogenic osteoarthritis rate. The
series presented includes 30 patients with tumors located in
the knee (26 cases), the lower tibia (one case), the upper
humerus (one case), the wrist (one case), and the talus (one
case).
t
v
taterial and method
etween 1992 and 2005, 30 patients (12 females and
8males), with a mean age of 36 years (range, 19—58), with
CT of the long bones were treated using the curettage and
ementation technique. Tumor type diagnosis was histolog-
cal based on surgical biopsies taken before any therapeutic
ct in all cases. All patients who had been operated on for
benign giant cell tumor conﬁrmed histologically with this
ethod were included retrospectively in the study. No diag-
osis was made on extemporaneous anatomical-pathological
ata.
Since histological grading of the benign GCT has not
roven to have a prognostic or therapeutic value and is no
onger used, it was not taken into account [6].
In 14 cases (46.66%), the tumor was located in the lower
emur, in 12 cases (40%) at the upper tibia, in one case at
he tibia, in one case at the upper humerus, in one case in
he wrist, and in one case in the talus.
The preoperative plain AP and lateral radiological analy-
is studied the following parameters:
tumor size: with a mean 71× 48-mm AP dimension and
71× 43-mm lateral dimension (range, 23—150mm);
ratio of the greatest tumor/bone diameter at the same
horizontal level. This ratio was a mean 68% (range,
50%—93%) anteroposteriorly and 75% (range, 50%—97%)
laterally. All the tumors studied therefore involved more
than 50% of the diameter of the bone involved;
mean volume calculated using the following formula:
0.5×D×d2. This calculation was valid considering that
GCT are roughly ellipsoid and regular in shape. This gave
a mean tumor volume of 78 cm3 (range, 36—203 cm3);
tumor position in relation to the cartilage: 22 tumors were
in direct contact with the joint cartilage (73%). This dis-
tance was evaluated on plain AP and lateral X-rays.
The preoperative CT or MRI studies showed extension toatment by curretage and cavity ﬁlling cementation 403
Three complications were noted: one leg deep venous thrombosis, one hematoma, and one
deep infection without impacting the initial treatment outcome over the long term.
Discussion: The curettage and cementation technique is usual practice in GCT treatment. Sim-
ple and reproducible, this technique has a lower rate of complication than other treatment
options such as cryotherapy. It produces a lower rate of recurrence with the dual beneﬁt of
excellent mechanical and functional qualities. Diagnosis of recurrence can be made earlier
because of the thin scalable border at the bone-cement interface. This technique does not
generally cause osteoarthritis, which was found in only two cases with no evidence of the
cement having a direct effect. The 30% recurrence rate observed in this series shows that the
beneﬁt provided by the cement as an adjuvant preservative remains modest.
Conclusion: The cement mechanical and cytotoxic properties as well as its innocuity and its ease
of handling make curettage and cementation one of the top-ranking GCT treatment options.he soft tissues in 12 cases (40%) (Fig. 1).
The indication for curettage and cementation surgery
ersus resection was based on the subjective apprecia-
ion of the mechanical stability expected after conservative
404 N. Fraquet et al.
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eFigure 1 Preoperative X-ray.
reatment by the surgical team managing the patient
Fig. 2). None of the patients presented pathological frac-
ure at the time of treatment.
The intervention consisted of meticulous curettage com-
leted by mechanical reaming of the walls, then ﬁlling the
ntraosseous cavity with polymethylmethacrylate cement.
efore polymerization of the cement, the curetted zone
ubmerged in cement was ﬁxed with an internal ﬁxator to
nsure optimal mechanical stability in 16 cases (11 plates,
hree plates + screws, and two with screws alone) (Fig. 3).
Adjuvant treatment was given in ﬁve cases: in three
ases, an aqueous solution of 80% phenol was applied on
he curetted wall with a compress, then rinsed in pure alco-
ol; this procedure was repeated three times. In two cases,
diphosphonate perfusion was given postoperatively.
The mean follow-up of this series was 6 years andmonths (range, 7months to 13 years).
None of the patients was lost to follow-up.
igure 2 Intraoperative view after curettage. Mechanical
eaming as a complement to curettage.
e
t
c
o
w
c
5
s
F
A
s
[
o
d
d
sigure 3 X-ray at 4 years of follow-up. No sign of osteoarthri-
is, no scalable border.
esults
ncological results
uring the clinical and radiological follow-up of the
atients who had received this treatment, nine recur-
ences (30%) were identiﬁed. Seven occurred in the 2 years
ollowing surgery (mean, 19months± 10months; range,
0—38months).
Recurrence was diagnosed based on visualization of a pro-
ressive scalable border on the plain X-rays taken during the
ollow-up visits. MRI conﬁrmed this and demonstrated the
xtension of the recurrence.
In six cases, the recurrence was found in the lower
xtremity of the femur. Three patients were treated with
otal knee arthroplasty, three with a second curettage and
ementation procedure. One recurrence at the upper tibia,
ne at the lower tibia, and one in the wrist were also treated
ith a second curettage and cementation procedure.
Of these recurrences, seven were in contact with the
artilage, two with extension to soft tissues.
The mean follow-up of these recurrences was
.5 years± 3 years (range, 1—13 years).
At the last follow-up of this study, no recurrence after a
econd curettage and cementation treatment was noted.
unctional results
t the last follow-up, the function of the operated limb was
tudied using the MSTS score described by Enneking et al.
8] to evaluate the functional result after tumor surgery.
The MSTS takes into account pain, function, acceptance
f the surgery, as well as assistance, limping, and walking
istance for the lower limb or position for the hand, and
exterity or elevation for the upper limb. In this series, the
core was a mean 93.33% (mean MSTS score, 28± 2/30).
cavity ﬁlling cementation 405
Figure 4 A. Window for curettage cementation. B. The sub-
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Radiographic results
At the last follow-up, four nonprogressive scalable borders
(15%) were found on plain radiographs out of 26 patients
(Fig. 3). The four patients who had had total knee replace-
ment had normal X-rays during the last follow-up visit, with
no loosening, no wear, and no sign of recurrence.
We also noted two cases of minimal osteoarthritis (one
impingement < 50% one simple condensation of the chon-
dral bone) requiring simple monitoring, one at the talocrural
joint and one at the upper extremity of the tibia, respon-
sible for genu varum with little progression. In these two
cases, the tumor was located at the contact with the carti-
lage, with extension to soft tissues. None of these cases of
osteoarthritis was symptomatic and did not require surgical
revision.
Early complications
Three complications were found, one case of sural phlebitis
and one hematoma at the operative site, which was not
revised. One patient developed sepsis in the surgical zone
(upper tibia) 2months after curettage and cementation. We
treated it with removal of the cement, lavage, then ﬁlling
with autograft plus biomaterials; the patient has experi-
enced no new septic complications.
Discussion
Treating GCT with curettage and cementation was described
by Vidal [9] in 1969; since then, this technique has become
current practice for treating this type of tumor, adopted
by a large number of surgical teams. Nevertheless, several
questions remain concerning the recurrence rate after per-
forming this technique, the toxic effect of the cement on
cartilage, and the value of systematic osteosynthesis.
It is commonly accepted that the tumor recurrence rate
after curettage and cementation treatment including ﬁll-
ing with analogous tissue or simple allograft, i.e., with
no adjuvant, ranges from 30 to 55% depending on the
series [1—3,6,10,14,15]. Use of an adjuvant reduces the
recurrence rate. Several methods have been proposed, for
example, use of a chemical agent such as phenol, but the
concentrations of this product authorized in France are too
low to make it effective [1,11].
Use of liquid nitrogen results in a 2—8% recurrence rate
[4,9,12], but this is a difﬁcult technique with frequent
complications, 30% according to Babinet [1]. Its use there-
fore remains rare in France.
Use of the cytotoxic properties of the cement can reduce
the recurrence rate to between 17 and 25% [1,2,13,14,16].
The present study had a 30% recurrence rate during the
ﬁrst 2 years, corresponding to a modest beneﬁt in terms of
recurrence.
This technique is criticized for its arthrogenic poten-
tial. GCT occur around the metaphyseal—epiphyseal area
of long bones and are therefore close to the joint cartilage.
In our study, 73% were in contact with the joint cartilage.
However, we only found 10% minimal osteoarthritis at the
last follow-up, with no functional repercussions. In addi-
tion, the causal relation between the intervention and the
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lhondral bone fractures. C. The remainder of the tibial plateau
etween A and B rolls on the cement block [1]. Plate osteosyn-
hesis prevents this effect.
eginning of osteoarthritis cannot be reliably established,
hatever the volume of cementation. This was conﬁrmed
y a March 2007 study in Sweden conducted by Vult von
teyern et al. [7], which noted no osteoarthritis progres-
ion at 9 years of follow-up. Moreover, the mean MSTS score
f 93.33% (28± 2/30) shows that the functional result of this
urgery is excellent at the longest follow-up.
Even though, no clinical study recommends systematic
steosynthesis to reinforce the cementation after curet-
age, we believe this is warranted. Babinet [1] described a
ead effect (Fig. 4), rolling of the remainders of the tib-
al plateau on the cement block, resulting in treatment
ailure. Osteosynthesis could prevent this failure mecha-
ism by interlocking the cement with the bony shell left
n place, thus promoting peripheral bone repair. No bead
ffect was found in our series, in which 16 patients (53.33%)
ad osteosynthesis reinforcement whenever curettage left
substantial cavity volume.
Finally, curettage and cementation treatment allowed
or early detection of recurrence [6,10,16,17] and there-
ore, early management. The cement forms a radiologically
omogeneous and dense mass, with the appearance of a pro-
ressive scalable border at the cement—bone interface that
s highly suggestive of recurrence, underscoring the impor-
ance of radiological follow-up every 4months for the ﬁrst
years in our view.
onclusion
CT can be treated easily and reproducibly with curettage
nd cementation with excellent and long-lasting functional
esults at the medium term. The arthrogenic effect that has
een blamed on the cement coming in contact with carti-
age has never been clearly demonstrated, even when used
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or ﬁlling voluminous cavities. In addition, the results of the
eries presented herein showed that none of the patients
reated with curettage and cementation suffered from sec-
ndary symptomatic osteoarthritis. All the mechanical and
ytotoxic properties of the cement, as well as its innocu-
usness and ease of handling give it the top ranking in
reatment of GCT, associated with osteosynthesis materials
n cases of large cavities after curettage in our study. The
0% recurrence rate shows that acrylic cement plays a small
ole as adjuvant. Other complementary treatments such as
iphosphonate or calcitonin are currently being studied in
n attempt to reduce the recurrence rate.
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